Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data-Reference-Cited by-同舟云学术

Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data

Published:2024-02-28 Issue:2 Volume:19 Page:213-221
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Olkus Alexander,Tomczak Aurelie,Berger Anne Katrin,Rauber Conrad,Puchas Philip,Wehling Cyrill,Longerich Thomas,Mehrabi Arianeb,Chang De-Hua,Liermann Jakob,Schäfer Sophia,Pfeiffenberger Jan,Jäger Dirk,Michl Patrick,Springfeld Christoph,Dill Michael T.^ORCID

Funder

Deutsche Krebshilfe

German Ministry of Research and Education

Universitätsklinikum Heidelberg

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11523-024-01044-1.pdf

Reference25 articles.

1. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428–44.

2. Kirstein MM, Vogel A. Epidemiology and risk factors of cholangiocarcinoma. Visc Med. 2016;32(6):395–400.

3. Lee W-S, Lee K-W, Heo J-S, Kim S-J, Choi S-H, Kim Y-I, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006;36(10):892–7.

4. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.

5. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cisplatin/durvalumab/gemcitabine;Reactions Weekly;2024-07-20

2. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study;Targeted Oncology;2024-05